English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Monoclonal antibodies against TNF-α, such as adalimumab, have been successfully implemented with treatment strategies for patients suffering from moderate to severe psoriasis who do not respond to or demonstrate contraindications for conventional treatment. We performed a retrospective analysis in 33 patients having received adalimumab for severe plaque-type psoriasis with or without arthritis focusing on quality of life using the DLQI questionnaire. During treatment with adalimumab the mean DLQI value significantly dropped from 20.5 to 6.4, which means an excellent increase in quality of life. 24 (72.7 %) patients described the treatment to be „very successful” and 20 (62.5 %) patients did not report any side effects. However, due to different reasons nine (27.3 %) patients got problems with continuous prescription of the drug. Adalimumab has a strong positive impact on improvement of quality of life in patients with severe psoriasis.

Verbesserung der Lebensqualität von Patienten mit Psoriasis unter Therapie mit Adalimumab